Regal Investment Fund Takes Responsibility for Investment Losses in Opthea, Writes Down to Zero

Summary

Regal Investment Fund’s Chief Investment Officer Phil King has taken responsibility for the losses incurred from its investment in Opthea, following the failure of a critical study questioning its feasibility. Regal holds 30% of Opthea and has written down this investment to zero, affecting returns for multiple funds’ investors. It is expected to have a significant impact on Regal’s equity strategy in March. This information is reported by the Australian Financial Review. Trading View

Impact Analysis

First-Order Effects: Regal Investment Fund faces immediate financial losses due to the failure of Opthea’s critical research study, which failed to meet the primary endpoint with opt-302 combined with aflibercept for patients with age-related macular degeneration. The write-down of Opthea’s investment to zero has a direct negative impact on Regal’s financial performance and equity strategy for March, affecting fund returns and investor sentiment. Trading View+ 2 Second-Order Effects: Opthea’s inability to achieve study success raises concerns about its operational viability and future funding capabilities, which may lead to loss of investor confidence and reduced stock price. Other investment funds like Hearts and Minds Investments have similarly written down their investments in Opthea to zero, indicating broader industry impacts. Trading View Investment Opportunities: Investors may explore options strategies such as hedging against potential further losses in Opthea or seeking alternative investments within the biotech sector that show more promise. The situation highlights risks associated with investing in biopharmaceutical companies with uncertain research outcomes. Trading View+ 2